CYBIN INC.
HELP · Pharmaceutical Preparations · EDGAR filings ↗
Grade
C59Clinical-stage psychedelics developer with ample near-term liquidity but no revenue, deep losses, and no de-risking pivotal readout disclosed.
Strengths
- Strong liquidity: current/quick ratio 7.7 (74th pct) and ~$94M cash (55th pct)
- Losses narrowed year over year (net income growth 71st pct)
Risks
- No revenue and deep negative returns (ROA -44%, ROE -48%)
- Binary clinical and ongoing funding/dilution risk with no positive pivotal trial result evidenced
Notable findings
- Notable holderHeld by 2 notable fund(s): CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC (as of 2026-03-31)
Key metrics
Return on equity
-47.7%
Return on assets
-43.7%
Current ratio
7.7×
Tangible book value
$129M
Cash & investments
$94M
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT05594667 ↗ | Effect of SSRIs on Response to Psilocybin Therapy Depression, Major Depressive Disorder | PHASE2 | Withdrawn | 2023-03-14 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 40-F | 2025-07-01 | 2025-03-31 | 0001628280-25-033606 ↗ |
| 40-F | 2024-06-26 | 2024-03-31 | 0001833141-24-000005 ↗ |
| 40-F | 2023-06-27 | 2023-03-31 | 0001833141-23-000004 ↗ |
| 40-F | 2022-06-22 | 2022-03-31 | 0001628280-22-017746 ↗ |